ABSTRACT
INTRODUCTION T

HE WORLD HEALTH ORGANIZATION estimated in 2003 that
there were approximately 35,000-110,000 HIV-infected Honduran children and adults (representing 1-3.2% of the total population). 1 At the time, this represented 60% of Central America's reported AIDS cases even though Honduras accounts for approximately 15% of the Central American population. 1 Most of these patients rely on the Ministry of Health (MOH) for their care and receive treatment at centers throughout Honduras. 2 Hospital Mario Catarino Rivas in San Pedro Sula (SPS) and Instituto Nacional del Torax Hospital in Tegucigalpa (TEG) are two such centers. These hospitals are major medical facilities that serve the HIV-infected populations in their respective cities.
Antiretroviral therapy (ART) in Honduras was available for only a small number of patients through varied nongovernmental organizations (NGOs) and through the private healthcare system prior to 2002. 2 Medications such as AZT, 3TC, DDI, D4T, ritonavir, indinavir, nelfinavir, and efavirenz were available in private wholesale pharmacies. 2 Black market medications obtained from developed countries were in some cases provided for free by humanitarian organizations. 3 The Honduran Congress then enacted a special emergency budget that provided funding to treat approximately 150 patients in late 2001. 4 This was followed by Global Fund approval of the Honduran National Strategic Plan in 2002, which provided further support for the fledgling antiretroviral program. 4 The Health Secretariat increased funding again in July of 2003 to introduce a comprehensive care program that included providing combi-nation antiretroviral therapy (CART). 4 During this period, the MOH rapidly increased the number of patients treated in the MOH program from 200 patients at the end of 2002 to 1880 patients by the end of 2003 (Dr. M. Urquia from the Honduran MOH, personal communication, 15 November, 2006) . Further expansion of access resulted in the MOH reporting to the United Nations General Assembly Special Session on HIV/AIDS in 2005 that over 4000 patients were receiving CART at care centers throughout Honduras. 4 The Honduran first-line CART regimen is AZT, 3TC, and efavirenz with allowance for substitution of D4T for AZT and nevirapine for efavirenz. 1 The potential for supply chain difficulties and the low genetic barrier to resistance of 3TC, efavirenz, and nevirapine are liabilities that threaten to rapidly yield resistance. Due to the limited availability of second-line medications, if resistance to the first-line agents were to become prominent, it would undermine the individual and population-level benefits that would otherwise accrue to the CART program.
In Europe and the United States, where ART use has been widespread for more than 10 years, the prevalence of baseline genotypic resistance is well studied and ranges from 10 to 27%. 5 In resource-constrained settings, where antiretroviral usage has only recently become more prevalent, genotypic resistance epidemiology is incompletely characterized because there have been few studies and the study samples have been small. 5 These reports indicate that there is a low prevalence of resistance ranging from 0 to 6%. 5 In South America, resistance in the CART era has been investigated in several countries over varied time periods. Except for a few studies showing higher rates, [6] [7] [8] available research shows that baseline resistance rates for each antiretroviral class range from 0 to 3%. [9] [10] [11] [12] [13] [14] [15] [16] [17] The largest South American study analyzed chronically infected Brazilians and estimated that resistance rates for each class of available antiretrovirals were 2-3%. 10 Notably, a more recent large Brazilian study showed an overall resistance rate of 12.7% in treatment-naive recently infected patients suggesting higher rates of resistance. 8 There are no studies that address resistance in treatment-naive patients from Central America. Therefore, we undertook a study to establish the point prevalence of genotypic resistance in a large cohort of Honduran patients who received care at two large metropolitan treatment centers during the early stages of the Honduran MOH ART program.
MATERIALS AND METHODS
Design
Following approval from each participating institution's Institutional Review Board and the Honduran MOH, identifier delinked preexisting discard serum specimens and related clinical data were used to conduct a retrospective point prevalence study. Eligible subjects were HIV-1-infected adult patients presenting for enrollment in the MOH antiretroviral treatment program. Serum was collected for storage at TEG or SPS between 
Specimen collection and processing
Sera were collected when the patients presented to the respective MOH clinics for comprehensive care and to initiate antiretroviral therapy if deemed appropriate. The MOH stored an aliquot of serum from each patient at Ϫ70°C with the intention of performing viral load testing in the future. Due to funding shortfalls, the specimens became earmarked for discard. Specimen retrieval entailed thawing, removal of 1 ml, and then refreezing of both original and study specimens. Following specimen retrieval and prior to removing patient identifying information, charts were reviewed to verify ART-naive status and record CD4 counts from the time of specimen collection. Specimens were then delinked and air-transported on dry ice to Lackland Air Force Base, San Antonio, TX, followed by overnight shipment to Walter Reed Army Institute of Research, Rockville, MD.
HIV viral RNA load determination
HIV-1 viral RNA concentration was determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) (Roche Amplicor HIV-1 Monitor Test, Version 1.5: Roche Diagnostics, Inc., Indianapolis, IN). Specimens were tested using the standard assay platform with a lower quantification limit of 400 HIV RNA copies/ml or the ultrasensitive method depending upon volume of specimen available. All specimens having undetectable HIV-1 viral RNA in the standard assay were retested using the ultrasensitive method (lower quantification limit of 50 HIV RNA copies/ml).
Serologic testing
Specimens having undetectable HIV-1 RNA or Ͻ50 HIV-1 RNA copies/ml were subjected to serologic testing in order to confirm the HIV-1 status of the specimen. The initial EIA screening was performed using the Genetic Systems rLAVA (Bio-Rad Laboratories, Redmond, WA). Repeat EIA testing was performed utilizing the Vironostika HIV-1 Microelisa System (Organon Teknika, Durham, NC). All samples found to be repeatedly reactive by EIA were subjected to confirmatory testing using the Bio-Rad HIV-1 Western Blot (Bio-Rad Laboratories, Redmond, WA) according to the manufacturer's recommendations.
Genotype testing
The sequences of the protease (PR) and reverse transcriptase (RT) genes were obtained using an in-house HIV-1 genotype assay procedure similar in execution to the Abbott (Applied Biosystems) ViroSeq Test. HIV-1 viral RNAs remaining from extractions performed for the ultrasensitive Roche Amplicor HIV-1 Monitor Test were amplified using the QIAGEN OneStep RT-PCR Kit (Valencia, CA). HIV-1 viral RNA was also extracted from 140 l to 500 l of serum using the QIAamp Viral RNA Mini Extraction Kit (Qiagen, Inc., Valencia, CA). Primers for amplification and sequencing reactions are given in Table 1 Protease-RT amplicons were purified by centrifugation through Amicon Micron-100 Microconcentrator columns (YM-100: Millipore Co., Billerica, MA). Purified amplicons were fractionated through 1.2% agarose E-gels (Invitrogen Co., Carlsbad, CA) and visualized by eithdium bromide UV fluorescence. The concentration of amplicons was determined by densitometer analysis of gel bands with extrapolation of mass from a standard curve derived from a DNA Mass ladder (Invitrogen Co., Carlsbad, CA). Fifty to 100 nanograms of protease-RT PCR amplicons was subjected to DNA sequence analysis using BigDye terminator cycle sequencing chemistry (Applied Biosystems, Inc., San Francisco, CA) and Half Dye (Sigma-Aldrich Co.) following cycling procedures recommended by Applied Biosystems. Seven to eight primers were used to obtain the sequence of the amplified protease/RT gene region (Table 1) . Sequencing reactions were clarified of unincorporated dye labeled terminators and salt by centrifugation through a 96-well separation plate purchased from Edge Biosystems (Gaithersburg, MD). Clarified sequencing reactions were dried under vacuum at a medium setting for 30 min (SpeedVac), dissolved in formamide, and loaded into the 3100 Genetic Analyzer (Applied Biosystems, Inc., Foster City, CA).
Sequence analysis
Consensus sequences were developed using the Sequencher version 4.1 software program (Genes Codes Corporation, Ann Arbor, MI). Double-stranded sequence coverage was obtained for all specimens analyzed. Relatedness among sequences and HIV-1 subtype was determined using the Neighbor Joining Maximum Likelihood Tree Bootstrap Value Analysis package. 18 All HIV-1 sequences were analyzed for HIV-1 drug-associated mutations using Stanford's Drug Resistance Algorithm (Version 4.0: http::hivdb.stanford.edu). HIV-1 subtype identification was further confirmed using programs provided by the National Center for Biotechnology Information (http://ncbi.nlm.nih.gov).
Gene mutation classification
Mutations were recorded as nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or major protease inhibitor (PI) based on the recommended mutation list for HIV drug resistance surveillance published by Shafer et al. 19 
Statistical analysis
Continuous variables (CD4 and VL) were compared using a two-sided Mann-Whitney U test. Categorical variables (proportion of specimens that possessed resistance) were compared using two-sided Pearson chi-square or Fisher's exact tests where appropriate. All statistical calculations were performed using Statistical Package for the Social Sciences (SPSS) version 13.0, Chicago, IL.
RESULTS
Specimens from 416 individuals were subjected to testing in this study. SPS had 166 and TEG had 250 specimens available from the predefined study period. Of the 416 study specimens, seven specimens were HIV-negative based on undetectable HIV RNA as well as EIA nonreactivity. Four (2.4%) HIV negative specimens were from SPS and three (1.2%, p ϭ 0.29) were from TEG. Of the 409 HIV-1-positive specimens, 41 (25%) from SPS and 32 (13%, p ϭ 0.001) from TEG could not be successfully sequenced. Inadequate HIV-1 viral load was the primary reason for not obtaining sequence data for these specimens. Seven specimens with greater than 1000 HIV-1 RNA copies/ml failed in sequencing reactions due to insufficient RNA yield. Thus, sequence data were obtained for 336 (81%) out of the original 416 study specimens for genotype analysis.
Sixty-nine percent of the HIV-1-positive specimens (283) had corresponding outpatient clinical records available for review. ART-naive status was confirmed in every available chart. The median CD4 count was 109 cells/l. Table 2 shows median counts for specimens from SPS and TEG. The CD4 count in SPS was higher than in TEG (p Ͻ 0.001). There was no difference in CD4 count between the sequenced (median ϭ 100 cells/l) and unsequenced specimens (median ϭ 146 cells/l, p ϭ 0.08). The median viral load was 4.88 log 10 copies/ml. As shown in Table 2 , viral loads were lower in SPS than in TEG (p ϭ 0.009). In addition, SPS had a greater frequency of having a viral load less than 400 copies/ml (p ϭ 0.02). HIV-1 sequences were aligned using DNASTAR LaserGene Software V6.0 (DNASTAR, Inc., Madison, WI). Clustal W method alignment indicated that five pairs of sequences had less than 0.1% sequence divergence. These sequences were identical except for mixed base calls. Two of these sequences harbored HIV-1 resistance mutations whose resistance profiles differed due to the locations of the mixed bases. The chromatographic profiles of all mixed base calls that resulted in drug resistance assignment were examined and drug resistance conferring mutations were maintained as per HIV-1 Resistance Genotype test rules. Ninety-five percent of the sequences had pairwise sequence divergence values ranging from 1.4 to 8.2%. Phylogenetic tree analysis using reference sequences for all HIV-1 subtypes showed that 100% of the sequences were HIV-1 group M and that 99.1% (333/336) of the sequences were HIV-1 subtype B. Two sequences from San Pedro Sula (03HN_CR075 and 03HN_CR150) were identified as subtype F1 and an AD recombinant, respectively. One sequence from Tegucigalpa (03HN_TX012) was identified as being HIV-1 subtype C. The three non-B subtypes had 8.1-14.2% sequence divergence. Clustering of sequences by region or mutation assignment was not evident in the phylogenetic tree.
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Overall, 9.2% of the specimens harbored clinically significant mutations that result in at least intermediate resistance to the Honduran first-line ART medications as defined by the Stanford Database Genotypic Resistance Interpretation Algorithm. In SPS, 14.0% of analyzed specimens harbored these mutations whereas only 6.5% of TEG specimens harbored these mutations (p ϭ 0.02). NRTI, NNRTI, and PI mutations were present in 26 (7.7%), 24 (7.1%), and 9 (2.7%) of the specimens, respectively. Each class of mutation was more frequent in SPS as shown in Table 2 . If V118I and V108I are counted as mutations, then the rates of NRTI and NNRTI mutations are 14% and 8.6%, respectively.
In the subset of sequenced specimens where ART-naive status was confirmed by retrospective chart review (n ϭ 239), 7.5% contained mutations conferring at least intermediate resistance (according to the Stanford Database Genotypic Resistance Interpretation Algorithm) to the Honduran first-line antiretroviral medications. In SPS, 10.6% of analyzed specimens harbored these mutations, whereas 5.8% of TEG specimens harbored clinically significant mutations (p ϭ 0.18). NRTI, NNRTI, and PI mutations were present in 15 (6.3%), 12 (5.0%), and 4 (1.7%) of the specimens, respectively. There was no significant difference in the frequency of mutations conferring at least intermediate resistance to the Honduran first-line regimen between specimens where charts were available versus those whose records were not accessible (p ϭ 0.09). The effect of CD4 count on resistance was also assessed. Overall, clinically significant resistance to the Honduran first-line regimen was detected in 1.6% (n ϭ 1), 8.5%, (n ϭ 5), 6.6% (n ϭ 4), and 13.6% (n ϭ 8) of patients in the first through fourth CD4 quartiles, respectively (p ϭ 0.10). Similarly, no significant association was found between CD4 quartile and resistance at either of the study locations (data not shown). Table 3 shows the frequency of mutations that were found in our cohort. The most common NRTI mutation was V118I (6.5%). However, V118I does not mediate resistance when present alone and is not a recommended mutation for use in epidemiologic genotypic resistance studies. 19 Conversely, M184V and T215F/Y (which confer clinically significant resistance to NRTIs) were present in 6.0% and 3.0% of specimens, respectively. K103N and Y188L (which confer high-level resistance to efavirenz) were each present in 3.0% and 1.2%, respectively. Each of these signature mutations was more common in SPS. PI mutations were uncommon in both SPS and TEG.
DISCUSSION
The World Health Organization guidelines for monitoring drug resistance suggest the emergence of transmitted drug re-LLOYD ET AL. 532 sistance will become a significant problem in resource-constrained countries that have recently initiated antiretroviral treatment programs. 5 Our study is the first to address the issue of baseline resistance in Central America. Our findings are strengthened by the relatively large cohort we studied. The Honduran protease inhibitor resistance rate is consistent with the low rates reported in several other South American studies. 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Honduran NRTI and NNRTI resistance rates were higher than most previous estimates, [10] [11] [12] [13] [14] [15] [16] [17] but there are also studies on drugnaive South American cohorts that show similar resistance rates. For example, two Brazilian studies found NRTI resistance rates greater than 10%. 6, 7 High baseline NRTI resistance rates have also been reported in Caribbean islands such as Martinique 20 and Cuba 21 where NRTI mutations were found in 24% and 7.4%, respectively. Equally high resistance rates have also been found in several drug-naive cohorts across the globe including the United States, [22] [23] [24] [25] Switzerland, 26 Poland, 27 Germany, 28 Canada, 29 and Israel. 30 Our finding of high NRTI and NNRTI resistance rates is also notable because we did not include V118I and V108I in our point estimates of ART class resistance rates. A notable finding of our study is that 9.2% of the specimens harbored clinically significant mutations that result in at least intermediate resistance (according to the Stanford Database Genotypic Resistance Interpretation Algorithm) to one of the first-line Honduran CART medications. This finding is of particular concern when viewed in the context of evolving research showing that virologic outcomes in newly infected treatmentnaive patients improve when therapy is modified based on genotypic resistance test results. [31] [32] [33] [34] Furthermore, if the baseline resistance rate worsens with expanded access to CART, then the long-term efficacy of the MOH treatment program could be threatened.
Our study was strengthened by analyzing baseline resistance at more than one treatment center, which allowed us to study a larger and more representative sample. The difference in baseline resistance noted between the two study centers was not expected. This result warrants further study since our investiga- 
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tion was not designed to investigate the reason for the disparity. The differences could certainly be due to higher rates of transmitted resistance in SPS prior to the study period. Being in a major port city, patients from SPS may have had more exposure to partners from regions where ART access was more widespread. Greater access to private sector and black market ART in the SPS local area prior to the initiation of the MOH program could also explain the difference observed. The duration of infection of TEG patients could also be longer than SPS patients (as evidenced by the lower average CD4 count and higher viral load seen in TEG). As a result, TEG patients would have acquired HIV infection at a time when the prevalence of transmitted resistance in Honduras was lower. Longer duration of infection could also increase the chance of reversion of some mutations to wild-type virus resulting in an underestimation of the true prevalence. Methodological limitations could also have affected the disparity between SPS and TEG and potentially inflated the overall baseline estimate of genotypic resistance. Specifically, some ART-experienced patients could have been included in our study. If this occurred more frequently in SPS, then the baseline resistance estimate in SPS would be inflated. There are several reasons why we do not think this happened. By definition, all patients were presenting to initiate treatment in MOH clinics and were thus "treatment-naive," and ART use in Honduras prior to 2002 was uncommon. [2] [3] [4] Furthermore, our retrospective chart review, which examined 70% of corresponding clinical records, confirmed ART-naive status in every case, and we found no significant difference in resistance rates between specimens that had charts reviewed and those where no chart was reviewed to verify ART-naive status. It is possible that some patients could have misunderstood the questions posed by the clinician during the intake history. Patients also could have been dishonest about their ART history, but there was no incentive to do so because the Honduran antiretroviral treatment program was (and is) available to all citizens in need, regardless of their prior ART history.
We chose to analyze the resistance data by using the Stanford Database Genotypic Resistance Interpretation Algorithm to identify specimens harboring mutations resulting in at least intermediate resistance to the Honduran MOH first-line regimen. Thus, we identified specimens that harbored virus that would likely result in clinical failure when the Honduran MOH regimen was applied. As a result, we have maximized the interpretive relevance of our findings for the Honduran setting while setting a benchmark for future surveillance studies that should guide MOH policy.
A potential limitation of our study is that we studied chronically infected patients (as evidenced by the low median CD4 count) instead of recently infected patients. Consequently, the current study may underestimate the true prevalence of genotypic resistance during the study period because transmitted mutations may become undetectable due to variable rates of replication fitness between mutated virions and nonmutated virions. We feel that the impact of this is minimal due to the growing body of literature showing that most transmitted mutations (especially thymidine analogue, K103N, and PI mutations) persist much longer than mutations that develop under ART pressure. [35] [36] [37] [38] However, the literature on persistence of drug mutations is not complete and some mutations have a propensity to revert to wild-type virus. For example, loss of M184V over a period of 1-3 years has been shown in several studies. 35, 37, 38 Mutations such as Y181C, 36 K219Q, 36 and D67N 37 also have been shown to revert to wild-type virus over variable periods. Thus, our reported prevalence for specific mutations could be affected, especially in TEG where subjects may have had a longer duration of infection (as evidenced by lower CD4 counts and higher viral loads). Despite this, the impact on our overall estimate of clinically significant resistance and our estimates or resistance by ART class should not be affected because the majority of mutations persist for many years.
In summary, we showed that clinically significant resistant virus was present in 9.2% of the patients presenting to initiate treatment in the early stages of the MOH antiretroviral treatment program. Significantly more resistance was found among samples collected at SPS as compared to TEG, demonstrating that genotypic resistance regional heterogeneity was already present at the outset of this program. Given the grave public health threat that resistance poses to the long-term effectiveness of the Honduran MOH ART program, further evaluation and monitoring of this program should include periodic determination of resistance rates as well as identification of risk factors for acquiring resistance. 
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